Press Releases Notable Labs, Ltd.

Equities

NTBL

IL0012002452

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
0.914 ^USD	-0.65%		-6.82%	-51.64%

Apr. 15	Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating	MT
Apr. 15	Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Notable Labs Reports 2023 Financial Results and Provides a Business Update	Apr. 15	AQ
Notable Labs Reports 2023 Financial Results and Provides a Business Update	Apr. 12	AQ
VASR BIOG : AACR 2024 VOLA Poster	Apr. 09	PU
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024	Apr. 09	AQ
VASR BIOG : AACR 2024 Poster	Apr. 08	PU
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform	Apr. 08	AQ
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform	Mar. 05	AQ
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment	Feb. 22	AQ
Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome	Dec. 18	AQ
Notable Labs to Participate in JMP Securities Hematology and Oncology Summit	Dec. 04	AQ
Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023	Nov. 14	AQ
Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML	Nov. 09	AQ
VASR BIOG : Letter from the CEO...	Nov. 08	PU
VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting	23-10-12	AQ
VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting	23-10-04	AQ
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC	23-09-06	AQ
VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT	23-08-28	BU
Vascular Biogenics: Q2 Earnings Snapshot	23-08-14	AQ
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update	23-08-14	AQ
Vascular Biogenics: Q1 Earnings Snapshot	23-05-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Notable Labs, Ltd.

Equities

NTBL

IL0012002452

Press Releases

Filters